Review

Cancer Immunology, Immunotherapy

, Volume 56, Issue 10, pp 1513-1537

First online:

Current approaches in dendritic cell generation and future implications for cancer immunotherapy

  • Sandra TuyaertsAffiliated withLaboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel
  • , Joeri L. AertsAffiliated withLaboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel
  • , Jurgen CorthalsAffiliated withLaboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel
  • , Bart NeynsAffiliated withMedical Oncology, Oncology Center, University Hospital Brussels, Free University Brussels
  • , Carlo HeirmanAffiliated withLaboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel
  • , Karine BreckpotAffiliated withLaboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel
  • , Kris ThielemansAffiliated withLaboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel
  • , Aude BonehillAffiliated withLaboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The discovery of tumor-associated antigens, which are either selectively or preferentially expressed by tumors, together with an improved insight in dendritic cell biology illustrating their key function in the immune system, have provided a rationale to initiate dendritic cell-based cancer immunotherapy trials. Nevertheless, dendritic cell vaccination is in an early stage, as methods for preparing tumor antigen presenting dendritic cells and improving their immunostimulatory function are continuously being optimized. In addition, recent improvements in immunomonitoring have emphasized the need for careful design of this part of the trials. Still, valuable proofs-of-principle have been obtained, which favor the use of dendritic cells in subsequent, more standardized clinical trials. Here, we review the recent developments in clinical DC generation, antigen loading methods and immunomonitoring approaches for DC-based trials.

Keywords

Clinical applicability Dendritic cell Cancer immunotherapy